Publications by authors named "E J D Mahoney"
Article Synopsis
- The study investigates how people with moderate-to-severe traumatic brain injuries (TBI) return to driving (RTD) and their driving habits over a two-year period following rehabilitation.
- Results show that 65% of participants returned to driving one year post-injury, increasing to 70% by the second year, but driving frequency and distance were lower than before the injury.
- Crash rates dropped from 14.9% before the injury to 9.9% in the first year and 6% in the second year, suggesting ongoing risks, but the study indicates that TBI patients may already be at a higher risk for crashes prior to their injuries.
Introduction: Some evidence suggests that cannabis may be a safer substitute for other drugs. Historically, sober living houses (SLHs) have been abstinence-based environments designed for individuals in recovery to live with others in recovery. However, the evolving legal landscape around cannabis use has left SLH operators and managers in a difficult position regarding policies related to cannabis use among residents.
View Article and Find Full Text PDFObjective: Many older adults in the United States with serious persistent mental illness reside in long-term facilities, and evidence suggests increasing numbers of long-term care residents with serious persistent mental illness. Healthcare professionals in these settings may face challenges in providing care to these residents. The purpose of this study was to describe health care professionals' perceptions of the barriers and facilitators to caring for long-term care residents with serious persistent mental illness.
View Article and Find Full Text PDFBackground: Sober living houses (SLHs) offer abstinence-based housing for people in recovery. Studies have shown that these supportive environments are associated with positive outcomes, yet little is known about why residents choose SLHs and their relationship to recovery outcomes.
Methods: Longitudinal data were collected from SLH residents who completed an interview six months after baseline (N = 462).
Article Synopsis
- GRN mutations lead to a condition known as FTD-GRN, which causes frontotemporal dementia; PR006 is a new gene therapy aimed at delivering the granulin gene using an adeno-associated virus.
- In initial studies, PR006 showed effectiveness in improving various pathological conditions related to FTD-GRN in animal models and was generally well tolerated in non-human primates.
- An ongoing human trial has reported that PR006 was safe for administration with some transient increases in progranulin levels in cerebrospinal fluid, although some patients experienced treatment-related adverse events, such as CSF pleocytosis and deep vein thrombosis.